On October 6, 2026, a clinical trial listing for anamorelin HCl was updated to reflect completed status. The trial, registered as NCT03743064, is titled "A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 2." It is a Phase 3 study. The trial examined anamorelin in adult patients with advanced non-small cell lung cancer who experience malignancy associated weight loss and anorexia. According to the listing, the study status is now recorded as completed.
Anamorelin remains classified as an unapproved compound used in research settings. This update reflects only a change in the trial's recorded status on ClinicalTrials.gov. No results, efficacy data, or safety findings are included in this update. Readers seeking further detail should consult the official trial record for additional information as it becomes available.
For more background on this compound, see the anamorelin overview page.